ISG
6.2.2024 15:01:33 CET | Business Wire | Press release
With the threat of recession still looming, two-thirds of European insurance industry leaders plan to expedite their digitalization programs to improve the customer journey and enhance operational efficiencies, according to new survey research from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.
The ISG "Pulse Check - State of the European Insurance Industry" survey, conducted in the fourth quarter of 2023, surveyed nearly 270 business decision-makers and IT leaders in the European insurance industry and found 66 percent plan to increase their digital investments in the next two years, including 68 percent who say they will invest in payment channels, 63 percent each in cybersecurity and augmented and virtual reality, and 59 percent in artificial intelligence.
Survey participants said their two main strategic priorities are acquiring new customers, identified as a top priority by 85 percent of respondents, and leveraging digital channels to develop new business opportunities (74 percent). Increased investments in digital offerings and personalized customer services will help drive customer acquisition and retention, the ISG report noted.
"’Digital first’ is the focus as European insurers implement next-generation technologies that promise the quickest return on investment for their core businesses and to improve their market position,” said Steve Hall, president of ISG EMEA and the firm’s chief AI officer. "Process and decision automation and data management will help create human-centered, technology-enabled businesses that leverage rapidly evolving digital technology to reshape work, lower costs and improve service. AI will undoubtedly be an additional accelerator.”
The survey found demand for artificial intelligence (AI) is experiencing particularly strong growth. Thirteen percent of respondents report their annual budget for AI is already set at more than €1 million, and six out of ten expect to receive additional funding in 2024. Enterprises indicate they plan to leverage large language models alongside established AI methods such as natural language processing and machine learning.
AI development is still at an early stage for many respondents, with half of companies (50 percent) experimenting with prototypes and only 6 percent actively developing enterprise-wide AI solutions. Eighteen percent of respondents say technologies such as augmented reality (AR) and virtual reality (VR) are being used to reduce business insurance losses through preventive maintenance.
Ninety-one percent of respondents consider improving the effectiveness of customer data management a critical investment priority. Data silos remain a challenge, with only about one-fifth of existing customer data being effectively utilized, according to the ISG research.
Cybersecurity is another area of focus as enterprises increasingly rely on digital infrastructure that may expose assets to business interruption and cyber-attacks. Investments in digital risk management will continue to increase, particularly in cybersecurity and AI, to offer “customer trust” as a key differentiator and meet increasing regulations. Sixty-three percent of respondents expect their cybersecurity budgets to increase between 2024 and 2026 in response to escalating risks and regulatory demands.
"Insurers are prioritizing investments in AI, legacy modernization and IT security. Strategic partnerships can increase access to digital capabilities, process knowledge and specialized talent while expanding market access and sharing development risk,” Hall added. "The share of organizations that see consolidation of their service provider portfolio as a top IT priority is growing significantly, from 59 percent in 2022 to 93 percent in 2023.”
Striking a balance between insourcing and outsourcing is critical given the evolving dynamics of the labor market and the need to attract and retain IT talent, the report said. The percent of survey respondents who plan to invest in insourcing (78 percent) is almost the same as the number who plan to invest in outsourcing (77 percent). Sixty-eight percent of decision-makers see improving talent management as a pressing business imperative.
"As tech companies and insurtech startups become more attractive employers for young, tech-savvy talent, traditional carriers are challenged to attract and retain top talent," Hall concluded. "High-quality talent management is becoming a critical factor in meeting transformative technology demands."
The ISG "Pulse Check – State of European Insurance Industry 2024” report is available for download on this website.
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206423163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
